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Premenopausal endogenous oestrogen levels and breast
cancer risk: a meta-analysis
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BACKGROUND: Many of the established risk factors for breast cancer implicate circulating hormone levels in the aetiology of the disease.
Increased levels of postmenopausal endogenous oestradiol (E2) have been found to increase the risk of breast cancer, but no such
association has been confirmed in premenopausal women. We carried out a meta-analysis to summarise the available evidence in
women before the menopause.
METHODS: We identified seven prospective studies of premenopausal endogenous E2 and breast cancer risk, including 693 breast
cancer cases. From each study we extracted odds ratios of breast cancer between quantiles of endogenous E2, or for unit or s.d.
increases in (log transformed) E2, or (where odds ratios were unavailable) summary statistics for the distributions of E2 in breast
cancer cases and unaffected controls. Estimates for a doubling of endogenous E2 were obtained from these extracted estimates,
and random-effect meta-analysis was used to obtain a pooled estimate across the studies.
RESULTS: Overall, we found weak evidence of a positive association between circulating E2 levels and the risk of breast cancer,
with a doubling of E2 associated with an odds ratio of 1.10 (95% CI: 0.96, 1.27).
CONCLUSION: Our findings are consistent with the hypothesis of a positive association between premenopausal endogenous E2 and
breast cancer risk.
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Many breast cancer risk factors are believed to operate through
circulating hormone levels; for example, early menarche, late
menopause, fewer full-term pregnancies and delayed first full-term
pregnancy. Specifically, early menarche and late menopause
implicate oestrogens, progesterone, or both in the aetiology of
breast cancer (Travis and Key, 2003). Incidence of breast cancer is
seen to increase sharply with age in premenopausal women, but
following the menopause, when oestrogen and progesterone levels
both drop, the rate of increase in risk with age is dramatically
reduced (Pike et al, 1993). The main mechanisms hypothesised to
explain how circulating hormones could increase breast cancer
risk are increased cell proliferation and mutagenesis (Pike et al,
1993; Travis and Key, 2003; Russo and Russo, 2004; Martin and
Boyd, 2008). Oestradiol (E2) has been shown to increase breast cell
mitosis in vitro (Key, 1999), and oestrogens and their metabolites
have been demonstrated to induce DNA damage, genetic
instability and cell mutations both in culture and in vivo (Travis
and Key, 2003). Higher levels of endogenous oestrogens have been
shown to be associated with an increased risk of breast cancer in
postmenopausal women; a pooled analysis of nine prospective
studies found that a doubling in the levels of E2 increased a
woman’s odds of developing breast cancer by 29% (95% CI: 15,
44%) (The Endogenous Hormones and Breast cancer Collabora-
tive Group, 2002). However, no such association has been
established in premenopausal women, possibly because of
difficulties in measuring premenopausal E2, which has cyclic
variation throughout the menstrual cycle (Key, 1999; Travis and
Key, 2003).
The evidence on endogenous premenopausal oestrogens and
breast cancer risk is mixed. Most studies have been fairly small,
and the largest study to date, which included around 300 breast
cancer cases, showed no evidence of an association. Breast cancer
is rare in women at young ages, which makes it difficult to
accumulate large numbers of cases prospectively. In addition, the
within-subject variation in oestrogen levels is greater in pre-
menopausal than postmenopausal women, giving rise to a greater
degree of attenuation of effects through regression dilution bias,
and this consequently limits the statistical power of individual
small studies. This is a strong motivation for a meta-analysis:
by pooling the estimates, the effective sample size is increased and
effects can be estimated with greater statistical power.
However, combining results from epidemiological studies that
differ to some degree in their designs and methods of statistical
analysis is always somewhat controversial, and here there are
several concerns. These probably contribute to the fact that no
formal meta-analysis has been carried out to date. First, combining
the results of the studies of endogenous oestrogen and breast
cancer is not completely straightforward, because of the different
ways in which studies have analysed and reported their results.
Some report odds ratios between quantiles of oestrogen, some as
an odds ratio per s.d. or unit increase in (log transformed)
oestrogen, and some only as the mean difference in oestrogen
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between cases and controls. However, provided assumptions
concerning the distribution of oestrogen are satisfied, it is possible
(Greenland and Longnecker, 1992; Chene and Thompson, 1996) to
estimate odds ratios for a unit increase in a risk factor even when
results are presented in one of the other ways described above, and
so this type of concern can be dealt with. We describe the methods
used to do this in detail under statistical analyses.
Dealing with methodological differences in the designs of the
individual studies is more problematic. There is substantial within-
subject variation in oestrogen levels across the menstrual cycle,
and it is possible that the relationship between oestrogen levels
and breast cancer risk differs according to the phase of the cycle.
Pooling results from studies conducted using oestrogen levels
measured in different phases may obscure this, as may merely
adjusting for phase (without taking account of a possible
interaction) within the individual studies. Further, the methods
used to adjust for phase in the menstrual cycle vary between
studies, from simple methods, such as matching on day of cycle or
stratifying on phase, to the more sophisticated approach of
obtaining residuals from spline regressions of the oestrogen curve
throughout the menstrual cycle. In addition, most studies adjust or
match for several other breast cancer risk factors, the choice of
which varies from study to study. These methodological differ-
ences will inevitably introduce a degree of heterogeneity into the
results of the studies and, given the available information from
each study, this heterogeneity cannot be completely removed
through careful statistical analysis. However, despite these
differences, we believe that as the studies are all investigating the
same basic question, a formal meta-analysis is justified. Such a
meta-analysis needs to acknowledge that the differences in study
design mean that it is virtually certain that there will be
heterogeneity in the magnitude of the observed associations and
to quantify this. If the extent of the heterogeneity was large, then
this would cast doubt on the validity of a pooled estimate.
We therefore carried out a systematic review of the literature to
identify all prospective studies of endogenous premenopausal
oestrogens on breast cancer risk. To estimate the effect of a
doubling of circulating premenopausal oestrogen levels on the risk
of breast cancer, we combined the results from seven prospective
studies, which include 693 breast cancer cases. We used a random-
effect meta-analysis to take account of the anticipated hetero-
geneity, resulting from the differences in methodology between
studies described above.
MATERIALS AND METHODS
Identification of studies
Studies were identified by performing a literature search on
Medline and Embase from 1950 to February 2009, of articles
containing the words ‘breast’ in combination with any of the terms
‘cancer’, ‘carcinoma’, ‘neoplasia’ or ‘tumour’ and the terms
‘estrogen’, ‘estriol’, ‘estradiol’, ‘estrone’, ‘hormone’ or ‘steroid’ in
the title. Articles were restricted to prospective studies of
circulating premenopausal oestrogens on breast cancer risk. The
search (carried out by KW) produced 7895 articles, of which 148
titles were identified as potentially eligible. Overall, 13 studies were
included based on their abstracts, but 6 were excluded after
reading the full-text articles, 2 because the subjects were all
postmenopausal, 2 because the cases were all a subset of one of the
studies included in the meta-analysis, and 2 studies measured
hormones other than oestrogens. The remaining seven studies
were all nested matched case–control studies (Wysowski et al,
1987; Helzlsouer et al, 1994; Rosenberg et al, 1994; Thomas et al,
1997; Kabuto et al, 2000; Kaaks et al, 2005; Eliassen et al, 2006). In
addition, the references of the selected articles and two review
articles (Key, 1999; Travis and Key, 2003) were manually searched,
but no additional articles were identified. No subjects were
included in more than one study; two studies included women
from the same cohort (Wysowski et al, 1987; Helzlsouer et al,
1994), but there was no overlap in participants selected for each
study. Matched odds ratios for quantiles or linear increases in log-
transformed E2, and all available summary statistics of (log
transformed) E2 in cases and controls, were extracted from each
study.
Statistical analyses
The distribution of E2 is positively skewed and a number of the
individual studies considered the effect of E2 on breast cancer risk
after logarithmic transformation of E2. We took the same
approach, and assumed that a log-normal distribution for E2 is
reasonable, so as to yield estimates of the odds ratio associated
with any multiplicative increase of circulating E2. We present the
odds ratio for a doubling of circulating E2. Strictly, odds ratios that
are adjusted for (and/or matched on) different sets of covariates
are not comparable (Steyerberg and Eijkemans, 2004). However, in
most instances such ‘heterogeneity bias’ is small and we judged it
preferable to use maximally adjusted estimates in the primary
meta-analysis, so as to minimise bias arising through confounding.
Where possible, as a check on the robustness of results, adjusted
and unadjusted odds ratios were estimated or extracted from the
individual studies.
The diversity in the ways in which results were reported meant
that a range of techniques were needed in order to estimate the log
odds ratio for a doubling in E2 and its standard error in the
various studies. Maximally adjusted, matched odds ratios were
calculated or extracted from all studies, except for Wysowski et al
(1987), where such estimates were not reported. The studies by
Rosenberg et al (1994) and Kaaks et al (2005) adjusted for phase in
the cycle, using spline regression as well as matching on day of
cycle, and we used the matched spline-adjusted estimates from
both studies. Rosenberg et al (1994) also reported the results of an
analysis using serial measurements of E2 on each woman, but we
used the results from their analysis of each woman’s first
measurement of E2 to be consistent with the other studies.
Three studies (Rosenberg et al, 1994; Thomas et al, 1997; Kabuto
et al, 2000) reported odds ratios for selected changes in
logarithmically transformed E2. Specifically, Thomas et al (1997)
reported the odds ratio for a unit increase in loge(E2), Kabuto et al
(2000) for a unit increase in log10(E2) and Rosenberg et al (1994)
for a 1 s.d. increase in spline-adjusted loge(E2). These estimates
(and corresponding standard errors) were used to directly estimate
the log odds ratio for a doubling of E2 and its standard error in
these studies.
In three further studies (Helzlsouer et al, 1994; Kaaks et al, 2005;
Eliassen et al, 2006), results concerning the log odds ratio in each
quantile of E2 compared with baseline were used to estimate the
log odds ratio for a doubling of E2 and its standard error, using the
method described by Greenland and Longnecker (1992). The
Greenland and Longnecker (1992) method requires estimates of
the mean loge(E2) in controls and the overall s.d. of loge(E2) in
order to estimate the mean of loge(E2) in each quantile, as
described by Chene and Thompson (1996). The mean and s.d. of
loge(E2) were estimated as the intercept and slope of normal
quantile–quantile plots of the quantiles of loge(E2), respectively,
separately for cases and controls. The pooled s.d. in cases and
controls was used as the overall s.d., after testing for evidence of a
difference in s.d. values in cases and controls using an F test. The
odds ratios reported by Kaaks et al (2005) are for quartiles of
residuals of E2 from a spline regression model used to model the
cyclic change in E2. Quartiles of the residuals in controls added to
the mean in controls were assumed to be the quartiles of E2 in
controls, adjusted for phase in cycle.
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In the study by Wysowski et al (1987), adjusted, matched
estimates were not presented, and so linear discriminant function
analysis (Hand et al, 1998) was used to obtain estimates of the log
odds ratio, and its standard error (ignoring the matching) from the
means of E2 in cases and controls. No measure of spread of E2 was
given in this paper. Accordingly, a pooled s.d. from the other six
studies was used. Methods used to estimate the s.d. of loge(E2) in
cases and controls for each study are summarised in Table 2.
We pooled the 10 estimates of s.d. of loge(E2) across cases and
controls and across studies, first pooling the luteal and follicular
estimates of s.d. from the study by Eliassen et al (2006) separately
in cases and controls. The means of E2 in cases and controls, along
with this pooled s.d., were used to estimate the mean of loge(E2)
in cases and controls (Weisstein, 2010), and hence the log odds
ratio for a doubling of E2 and its standard error.
The above sections describe the way in which our best estimates
of the log odds ratio and its standard error were obtained in
each study. In addition, in five of the studies (Helzlsouer et al,
1994; Rosenberg et al, 1994; Thomas et al, 1997; Kaaks et al, 2005;
Eliassen et al, 2006) it was possible to obtain estimates using more
than one approach, and we compared these estimates within
studies. The sensitivity of the meta-analysis to the choice of
estimation method was also examined. This allowed a comparison
of matched estimates (using reported matched estimates or by
implementing the Greenland and Longnecker (1992) method) and
unadjusted estimates ignoring the matching (by implementing
Discriminant Function Analysis; Supplementary Table 1).
The individual study estimates were combined using a random-
effect meta-analysis, as described by DerSimonian and Laird
(1986). A random-effect approach was used, as we anticipated
some heterogeneity in study-specific effects due to the methodo-
logical differences between studies. The random-effect meta-
analysis uses both the variance of the study-specific results and
the estimated between-study variance in results to assign weights
to the individual studies. This results in more homogeneous
weights than a fixed-effect inverse-variance weighted meta-
analysis. Between-study heterogeneity was assessed using
I2-statistics and Cochran’s Q-statistic. Publication bias was
explored using funnel plots and Galbraith plots (Galbraith, 1988).
Eliassen et al (2006) collected two blood samples from each
woman, one from each of the follicular and luteal phases of the
menstrual cycle, and reported separate odds ratios for each phase.
As oestrogen levels within women are correlated (Missmer et al,
2006), the meta-analysis was carried out twice, once including the
follicular estimate and once the luteal estimate from this study.
Helzlsouer et al (1994) stratified their analysis by follicular and
luteal phase, with measurements in each phase from different
women, and we pooled the two estimates before including them in
the meta-analysis.
Two of the studies also reported the association between breast
cancer risk and circulating levels of free E2 (Kabuto et al, 2000;
Eliassen et al, 2006), an estimate of the amount of circulating E2
that is unbound to sex hormone binding globulin. The meta-
analysis was repeated using the same methods described above to
obtain a combined estimate of the odds ratio for breast cancer with
a doubling of free E2.
RESULTS
The seven studies, which provided 693 breast cancer cases and 1609
controls, are summarised in Table 1. Four studies were from US
populations (Wysowski et al, 1987; Helzlsouer et al, 1994; Rosenberg
et al, 1994; Eliassen et al, 2006), two from European populations
(Thomas et al, 1997; Kaaks et al, 2005) and one from a Japanese
population (Kabuto et al, 2000). The age ranges of the women in the
studies were similar, from approximately 25 to 55. Six out of seven
studies matched on time in menstrual cycle (Wysowski et al, 1987;
Helzlsouer et al, 1994; Rosenberg et al, 1994; Thomas et al, 1997;
Kaaks et al, 2005; Eliassen et al, 2006), and all studies matched on
some other factors such as demographic or reproductive factors
(Table 1), but estimates from the matched analyses were available for
only six of the studies. In two of the studies, women were known to be
premenopausal at the time of their breast cancer diagnosis
(Wysowski et al, 1987; Helzlsouer et al, 1994). In all but one of the
studies (Wysowski et al, 1987; Helzlsouer et al, 1994; Rosenberg et al,
1994; Thomas et al, 1997; Kaaks et al, 2005; Eliassen et al, 2006) it is
stated that women using hormonal contraceptives at the time of the
blood draw were excluded. Two of the seven studies were limited to
invasive breast cancer cases (Rosenberg et al, 1994; Kaaks et al, 2005).
Table 2 reports estimates of the geometric mean and geometric
s.d. of E2 in cases and controls, within each study. The pooled
geometric s.d. was close to 2 (1.91), indicating that levels 1 s.d.
above the (geometric) mean were approximately double the
geometric mean, while levels 1 s.d. below the geometric mean
were approximately half of it. The estimated odds ratios for a
doubling of E2 for each study, with a pooled odds ratio from the
random-effect meta-analysis, (a) including the luteal estimate from
the study by Eliassen et al (2006) and (b) using the follicular
estimate from this study, are summarised in Figure 1. There was
weak evidence of a positive association between circulating levels
of E2 and breast cancer risk, with a doubling of E2 conferring a
10% (95% CI: 4, 27; P¼ 0.08) to 14% (95% CI: 2, 32; P¼ 0.17)
increase in the odds of developing breast cancer, depending on
which estimate is included from the Eliassen et al (2006) study.
Assuming that E2 is approximately log-normally distributed with
geometric s.d. 1.91, our more conservative estimate equates to
distributions in cases and controls 0.091 (95% CI: 0.039, 0.222)
s.d. values apart and hence to an odds ratio of 1.26 (95% CI: 0.90,
1.76) comparing women in the top and bottom quartiles of E2.
Table 3 reports estimated odds ratios for a selection of percentage
increases in E2.
The combined estimated odds ratio for a doubling of free E2
(from the two studies that provided estimates) was 1.27 (95%
CI: 1.00, 1.61) or 1.41 (95% CI: 1.13, 1.74) when including the
luteal and follicular estimates from Eliassen et al (2006) study,
respectively. For comparison, the equivalent estimates for total E2
for the same two studies were 1.29 (95% CI: 0.97, 1.70) or 1.36
(95% CI: 1.08, 1.70), respectively.
There was little evidence of between-study heterogeneity, with
the proportion of variability between studies falling between 20%
and 33%, depending on which estimate was included from the
study by Eliassen et al (2006). The funnel plots and Galbraith plots
showed no evidence of publication bias. The results of the meta-
analysis were not substantially affected by the methods used to
estimate the dose–response effect estimates: the pooled random-
effect estimate from unadjusted estimates ignoring the matching,
for a doubling of E2, where available (using Discriminant Function
Analysis in six of the studies and the reported unadjusted matched
estimate from the study by Kabuto et al (2000)), was 1.08 (95% CI:
0.98, 1.20) and 1.12 (95% CI: 1.00, 1.26), when including the luteal
and follicular measurements from Eliassen et al (2006) study,
respectively. Within studies, the unadjusted odds ratio ignoring
the matching was very close to the adjusted matched odds ratio for
four out of five of the studies where it was possible to estimate
odds ratios using two methods (Supplementary Table 1).
DISCUSSION
Our analysis provides some evidence of a positive association
between circulating E2 levels and breast cancer risk in premeno-
pausal women. We estimate that a doubling of circulating E2
increases a woman’s risk of breast cancer by 10% (95% CI: 4, 27).
The breast cancer odds ratio for a doubling of postmenopausal
E2 has been estimated to be 1.29 (95% CI: 1.15, 1.44; The
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Endogenous Hormones and Breast cancer Collaborative Group,
2002), which is larger than our estimate for premenopausal E2. The
confidence intervals overlap, however, and it is therefore still
unclear whether there is a different effect of circulating E2 in
women before and after the menopause. Within-subject variability
in E2, which is likely to be substantially larger in premenopausal
than postmenopausal women, will dilute the effect estimate,
and this could contribute to the difference in the estimates.
The majority of breast cancer cases in the meta-analysis are likely
to be premenopausal, and there may be differences in the aetiology
Table 2 Estimated geometric mean and geometric s.d. E2 in cases and controls for each study, and the estimation methods used
Estimated geometric mean (s.d.) E2
Study Cases Controls Method used to estimate s.d. loge(E2) in cases and controls
Wysowski et al (1987) 84.8 (1.91) 101.5 (1.91) Pooled s.d. across cases and controls from all other studies
Helzlsouer et al (1994) 44.7 (3.00) 47.9 (NA) Two quantiles in cases (median in cases plus a further quantile calculated from no. of cases
above and below control median) on a Q–Q plot used to estimate s.d. E2 in cases. s.d. loge(E2)
calculated from mean and s.d. E2, assuming a normal distribution for loge(E2)
Rosenberg et al (1994) 137.0 (2.19) 138.4 (2.01) s.d. loge(E2) in cases and controls reported
Thomas et al (1997)a 86.0 (1.72) 77.0 (1.72) Geometric mean E2 in cases and controls, with 95% CIs, reported
Kabuto et al (2000) NA 87.4 (2.03) s.d. log10(E2) in controls reported
Kaaks et al (2005)a 86.3 (1.97) 80.5 (2.03) s.d. loge(E2) calculated from mean and s.d. E2, assuming a normal distribution for loge(E2),
separately for cases and controls
Eliassen et al (2006)
(follicular)
49.4 (1.73) 43.8 (1.82) Quartiles plus median, 12.5th and 87.5th percentiles E2 on a Q–Q plot used to estimate mean
and s.d. E2. s.d. loge(E2) calculated from mean and s.d. E2, assuming a normal distribution for
loge(E2), separately for cases and controls
Eliassen et al (2006) (luteal) 120.3 (1.43) 117.9 (1.55) As above, separately for luteal E2
Abbreviations: CIs¼ confidence intervals; NA¼ not applicable; Q–Q¼ quantile –quantile plot. aThomas et al and Kaaks et al report the mean E2 in pmol l1. These were
converted to pgml1 by multiplying by 0.272.
Table 1 Summary of the characteristics and main findings of the studies in the meta-analysis
Study
Cases/
controls
Age
range
(years) Cohort
Effect
estimate
from main
analysis
Main result
(95% CI)a
Matched or adjusted
for time in cycle?
Additionally adjusted
for/matched on
Wysowski et al
(1987)b
17/67 25–50 Washington
County
Mean difference in
matched cases vs
controls
Mean difference
not reported (P for
difference 4 0.05)
Matched to exact days
since last cycle
Age, race
Helzlsouer et al
(1994)
22/44 25–54 Washington
County
OR for above vs
below median E2
0.7 (0.2, 3.1) Matched to within 1 day
since last cycle + luteal and
follicular samples analysed
separately
Age, race, time of day of
blood draw, interval
between last meal and
blood draw
Rosenberg et al
(1994)
79/306 34–55 NYU Women’s
Health Study
OR for 1 s.d.
increase in residual
logeE2 from spline
regression
1.19 (0.91, 1.55) Matched to exact day since
last cycle + spline adjusted
Age, date of blood draw,
no. of blood samples
Thomas et al
(1997)
61/179 33–49c Guernsey OR for 1 unit
increase in loge E2
1.51 (0.87, 2.63) Matched to within 2 days
to next cycle
Age, parity, first-degree
family history breast cancer,
BMI, past OC use, other
hormone concentrations,
date of blood draw
Kabuto et al
(2000)
46/94 NA Atom bomb
survivors Hiroshima
and Nagasaki
OR for 1 unit
increase in log10E2
3.6 (1.1, 13.4) Not matched or adjusted
for
Age, city, date of blood
draw, radiation dose
Kaaks et al
(2005)
283/551 37–53c EPIC OR for quartiles
of residual E2 from
spline regression
1.0 (0.66, 1.52) Matched on categories of
days to next/last cycle +
spline adjusted
Age, study centre, BMI, age
first pregnancy, age
menarche, no. children,
time of day of blood draw
Eliassen et al
(2006)
185/368 37–50c Nurses’ Health
Study II
OR for quartiles
of E2
Follicular phase: 2.1
(1.1, 4.1), luteal
phase: 1.0 (0.5, 1.9)
Adjusted for days from last
cycle (follicular samples) or
days to next cycle) luteal
samples) + luteal and
follicular samples analysed
separately
Age, BMI at the age of 18
years, age at menarche, age
first birth, parity, history
benign breast disease,
family history breast cancer,
ethnicity, time of day of
blood draw
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; NA¼ not applicable; OC¼ oral contraceptive; OR¼ odds ratio. aWhere OR for quantiles of E2 were reported, the
result is for the top vs bottom quantile. bAlthough their analysis was matched, only unmatched estimates were presented in the paper. cIndicates 5th to 95th percentile.
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of premenopausal and postmenopausal breast cancer, which result
in oestrogen levels influencing breast cancer risk to a lesser extent
before the menopause. For example, premenopausal breast cancers
are more likely to be oestrogen receptor negative and therefore not
sensitive to oestrogen (Vasiljevic et al, 1998). Perhaps circulating
premenopausal oestrogen has a different effect on breast cancer
risk than circulating postmenopausal oestrogen; premenopausal
E2 is produced predominantly in the ovaries, while in post-
menopausal women circulating levels are much lower, and
production is predominantly by conversion of androgen pre-
cursors in adipose tissue into oestrone, which is then converted
into E2 (Travis and Key, 2003). We estimated the geometric s.d. of
E2 to be 1.91 in premenopausal women, while the geometric s.d. in
postmenopausal women, estimated from the lower and upper
quartiles of E2 in the published pooled analysis (The Endogenous
Hormones and Breast cancer Collaborative Group, 2002) using a
Q–Q plot, is 1.67. This is consistent with within-subject variability
being somewhat greater in pre- than postmenopausal women, but
nonetheless the total variability on the multiplicative scale appears
to be sufficiently similar for informal comparisons of the effect
of a doubling of levels to be made.
The endogenous androgens testosterone, androstenedione,
DHEA and DHEAS, which do not have the cyclical variation of
oestrogen, have been found to have similar effects on breast cancer
risk in premenopausal and postmenopausal women. Odds ratios
for breast cancer for premenopausal women in the top vs bottom
quartiles of several androgens in the study by Kaaks et al (2005)
range from 1.5 to 1.7 , while for postmenopausal women in the top
vs bottom quintiles of the same androgens, the estimates range
from 1.7 to 2.2 (The Endogenous Hormones and Breast cancer
Collaborative Group, 2002). This supports the argument that one
contributory factor to the difference in estimates for premeno-
pausal and postmenopausal E2 could be increased within-subject
variability before the menopause.
Rosenberg et al (1994), however, report an estimate using the
mean of several E2 measurements from the same women, thus
reducing measurement error in the exposure. This result, which
was not included in our meta-analysis, shows a similar association
between oestrogen and breast cancer risk to their estimate using a
single E2 measurement, whereas a stronger association would
be expected if measurement error really was biasing the result
towards the null.
All studies used E2 as the exposure, and in addition oestriol was
measured in one study (Wysowski et al, 1987) and four studies
measured oestrone (Wysowski et al, 1987; Helzlsouer et al, 1994;
Kaaks et al, 2005; Eliassen et al, 2006). E2 was chosen as the
exposure for the meta-analysis because it is the predominant
oestrogen in premenopausal women (Herjan, 2004), and was
measured in all seven studies. The estimates of the effects of
circulating oestrone on breast cancer risk were similar to those of
circulating E2 in the four studies, in which both oestrogens were
measured, albeit with somewhat larger effect estimates for luteal
oestrone than luteal E2 (but similar estimates for follicular
oestrone and E2) in the study by Eliassen et al (2006).
All studies included in the meta-analysis matched cases and
controls. All estimates in the primary meta-analysis are from fully
matched/adjusted analyses, apart from those from the study by
Wysowski et al (1987). However, different studies match and
adjust for different factors, including measures of adiposity,
reproductive factors and family history of breast cancer. One study
reported adjusted and unadjusted (matched) estimates (Eliassen
et al, 2006) and found that estimates adjusting for BMI at the age of
18 years, age at menarche and first birth, parity, history of benign
breast disease and family history of breast cancer, were only
slightly larger than unadjusted (matched) estimates. We also found
that within studies our estimate of the odds ratio ignoring the
matching and adjustment was very close to the adjusted matched
odds ratio for all studies where we were able to estimate both,
except for the study by Rosenberg et al (1994), in which matching
and adjustment changed the estimate from close to one to a
modest, but nonsignificant association. Carrying out a meta-
analysis where we used estimates ignoring matching and adjust-
ment (where possible) gave very similar results to those where we
did allow for matching and adjustment. These findings, together
with the reasonably low between-study heterogeneity, imply that
our combined estimates are reasonably robust to differences in
matching and adjustment between studies.
We assumed in our analysis that a log-normal distribution for
E2 is reasonable. In three of the studies (Rosenberg et al, 1994;
Thomas et al, 1997; Kabuto et al, 2000) it is explicitly stated that E2
was log-normally distributed. In addition, the 12.5th and 87.5th
percentiles of E2, reported by Eliassen et al (2006) study, are
equidistant from their reported median, after log transformation,
which means that log transformation removes the positive skew
Table 3 Estimated ORs for a range of percentage increases of circulating E2
Including luteal
measurements from
Eliassen et al study
Including follicular
measurements from
Eliassen et al study
Increase in E2 OR (95% CI) OR (95% CI)
10% 1.01 (0.99, 1.03) 1.02 (1.00, 1.04)
20% 1.03 (0.99, 1.06) 1.04 (1.00, 1.08)
50% 1.06 (0.98, 1.15) 1.08 (0.99, 1.18)
100% (doubling) 1.10 (0.96, 1.27) 1.14 (0.98, 1.32)
400%a 1.25 (0.91, 1.73) 1.36 (0.96, 1.91)
Abbreviations: CI¼ confidence interval; OR¼ odds ratio. aCorresponds approxi-
mately to a woman in 90th percentile E2 compared with a woman in 10th percentile.
Odds ratio
0.8
Wysowski et al (1987)
Helzlsouer et al (1994)
Rosenberg et al (1994)
Thomas et al (1997)
Kabuto et al (2000)
Kaaks et al (2005)
Eliassen et al (2006) (follicular)
Eliassen et al (2006) (luteal)
Overall including et al Eliassen
study follicular I2=32.8%
Overall including from Eliassen
study I2=19.9%
Odds ratio (95% CI)Study
0.75 (0.42, 1.32)
0.94 (0.65, 1.37)
1.29 (0.91, 1.84)
1.33 (0.91, 1.95)
1.47 (1.00, 2.15)
1.01 (0.86, 1.18)
1.30 (0.98, 1.73)
1.10 (0.74, 1.66)
1.14 (0.98, 1.32)
1.10 (0.96, 1.27)
321.51.210.3 0.5
Figure 1 Breast cancer odds ratios for a doubling of endogenous E2
within studies and pooled estimates across studies. Note that the size of
each box is proportional to its weight in the meta-analysis that included the
follicular estimate from the Eliassen et al (2006) study, apart from the light
grey box, which has size proportional to its weight in the meta-analysis
including the luteal estimate from Eliassen et al (2006) study. The relative
weights in the meta-analysis including the follicular estimate from Eliassen
et al (2006) were (in the same order as the graph) 0.06, 0.12, 0.13, 0.11,
0.11, 0.30, 0.17, and for the study including luteal estimate from Eliassen
et al (2006) were 0.06, 0.12, 0.13, 0.11, 0.11, 0.37, 0.10.
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observed in their data. Similarly, the 25th and 75th percentiles of
the residuals of E2 in controls from the spline regression carried
out by Kaaks et al (2005) are equidistant from their median
after log transformation. It seems therefore that a log-normal
assumption is reasonable.
It is possible that the effect of a doubling of E2 on breast cancer
risk differs according to the phase of the menstrual cycle. This,
coupled with the fact that different methods were used to match or
adjust for time of blood sample collection in the menstrual cycle in
the various studies, may limit the utility of a single pooled
estimate. However, a number of factors suggest that our pooled
estimate may well be generalisable to the different phases of the
cycle. First, we did not find any statistically significant evidence of
heterogeneity in the magnitude of associations across studies.
Second, although one study (Eliassen et al, 2006) did report weak
evidence of an association in the follicular phase, but not in the
luteal phase, confidence intervals on the magnitude of the
associations in the two phases were wide and they did not report
the result of a statistical interaction test for a difference between
these (Matthews and Altman, 1996). Third, in a previous study
(Walker et al, 2009) we took repeated measurements of urinary
oestrone glucuronide, a principal metabolite of serum oestrogens
that is highly correlated with serum E2 (Tanabe et al, 2001), in
premenopausal women, and estimated the association at different
times in the menstrual cycle with mammographic density, a very
strong marker of breast cancer risk. We found that the mean level
of oestrone glucuronide throughout the cycle is the most
biologically relevant measure associated with mammographic
density, rather than that in any particular phase in the cycle.
This provides us with some evidence that our pooled results
are not materially affected by the different ways in which time in
the menstrual cycle was accounted for.
In postmenopausal women, circulating levels of free E2 were
found to have a larger effect on breast cancer risk than total E2
(The Endogenous Hormones and Breast cancer Collaborative
Group, 2002). We estimated a similar increased risk in breast
cancer for a doubling of free E2 and a doubling of total E2;
however, there was a large amount of uncertainty in both estimates
as only two studies provided estimates of the association with
free E2. We have no evidence to suggest that circulating levels
of free E2 are more strongly associated with breast cancer risk than
total E2 in premenopausal women.
Helzlsouer et al (1994) and Eliassen et al (2006) both report
results stratifying by phase in the menstrual cycle, and both found
a stronger association with breast cancer in the follicular than the
luteal phase. The study by Thomas et al (1997) showed that the
difference in E2 between cases and controls was greatest in the
mid-cycle, at the transition between the follicular and luteal
phases, but this was based on only seven cases in the mid-cycle. It
remains to be seen whether E2 levels at a particular point in the
cycle are more important in the aetiology of breast cancer than the
average level over time.
It is worth considering whether a woman’s circulating E2 level
could be added to models for projecting the risk of breast cancer,
such as the Gail model or the ‘Gail model 2’ (Costantino et al, 1999).
Gail (2008) demonstrated that adding seven single-nucleotide
polymorphisms to the ‘Gail model 2’, each of which confers an OR
of between 1.07 and 1.26 and has a carrier frequency of between 0.13
and 0.50, added very little discriminatory accuracy to the prediction
model. If premenopausal women in the top quartile of circulating E2
carry an increased risk somewhere in the region of 25% compared
with those in the bottom quartile, adding E2 level to the model would
do little to improve its prognostic accuracy.
This meta-analysis has demonstrated weak evidence of a
positive association between premenopausal endogenous E2 levels
and breast cancer risk. More studies are needed to accurately
quantify this association, in order to provide meaningful estimates
and to allow a comparison with the association in postmenopausal
women. Repeated measurements in each woman may be helpful
to reduce measurement error in E2. Further estimates in the
follicular and luteal phases of the cycle separately would aid
the discussion of whether E2 in a particular phase in the cycle
is important, or whether mean levels across the cycle are
implicated.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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